Perseverance Research Center — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$519,180	48
2024	Research	$401,541	84
2022	Research	$4,996	1

Breakdown

Who paid Research payments · program years 2022–2025

E.R. Squibb & Sons, L.L.C. $309,827 5 payments
Genzyme Corporation $214,762 27 payments
Jazz Pharmaceuticals Inc. $195,137 86 payments
Organogenesis Inc. $191,593 10 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $5,996 2 payments
Celgene Corporation $4,500 1 payment
Ucb SA $3,902 2 payments

Studies the money was for Research payments · program years 2022–2025

A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $224,267 2 payments
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis $198,326 25 payments
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (Xywav) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia Or Narcolepsy $195,137 86 payments
PREPARE PuraPly AM/XT $167,968 9 payments
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $83,163 1 payment
PREPARE PuraPly AM/XT study $23,625 1 payment
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $16,436 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deuterated [D6]-Dextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $5,996 2 payments
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. $5,828 2 payments
An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures $3,832 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.